UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (123) 123
life sciences & biomedicine (117) 117
oncology (91) 91
humans (88) 88
female (53) 53
male (51) 51
lung cancer (49) 49
lung neoplasms - drug therapy (47) 47
middle aged (46) 46
aged (43) 43
carcinoma, non-small-cell lung - drug therapy (42) 42
lung neoplasms - pathology (38) 38
adult (34) 34
respiratory system (34) 34
carcinoma, non-small-cell lung - pathology (28) 28
lung cancer, non-small cell (26) 26
cancer (23) 23
aged, 80 and over (22) 22
lung neoplasms - genetics (21) 21
mutation (21) 21
treatment outcome (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
chemotherapy (19) 19
clinical trials (19) 19
cancer therapies (18) 18
care and treatment (18) 18
neoplasm staging (17) 17
patients (17) 17
lung neoplasms - mortality (15) 15
abridged index medicus (14) 14
carcinoma, non-small-cell lung - genetics (14) 14
immunotherapy (14) 14
lung neoplasms - therapy (14) 14
antineoplastic agents - therapeutic use (13) 13
carcinoma, non-small-cell lung - mortality (13) 13
general & internal medicine (13) 13
hematology, oncology and palliative medicine (13) 13
metastasis (13) 13
non-small cell lung cancer (13) 13
nsclc (13) 13
non-small cell lung carcinoma (12) 12
pulmonary and respiratory medicine (12) 12
antibodies, monoclonal, humanized - therapeutic use (11) 11
carcinoma, non-small-cell lung - metabolism (11) 11
disease-free survival (11) 11
lung neoplasms - metabolism (11) 11
medicine, general & internal (11) 11
tumors (11) 11
analysis (10) 10
kaplan-meier estimate (10) 10
lung neoplasms - immunology (10) 10
quality of life (10) 10
survival analysis (10) 10
carcinoma, non-small-cell lung - immunology (9) 9
double-blind method (9) 9
lung cancer, small cell (9) 9
prognosis (9) 9
apoptosis (8) 8
carcinoma, non-small-cell lung - therapy (8) 8
cell line, tumor (8) 8
clinical trials as topic (8) 8
erlotinib (8) 8
pembrolizumab (8) 8
pulmonary/respiratory (8) 8
research (8) 8
usage (8) 8
antibodies, monoclonal, humanized - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
biomarkers (7) 7
erbb receptors - genetics (7) 7
melanoma (7) 7
metastases (7) 7
ramucirumab (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
young adult (7) 7
animals (6) 6
antibodies, monoclonal - administration & dosage (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
biomarkers, tumor - metabolism (6) 6
disease progression (6) 6
egfr (6) 6
epidermal growth factor receptors (6) 6
follow-up studies (6) 6
health aspects (6) 6
immunotherapy - methods (6) 6
molecular targeted therapy (6) 6
non-small-cell lung cancer (6) 6
pd-l1 protein (6) 6
programmed cell death 1 receptor - antagonists & inhibitors (6) 6
science & technology - other topics (6) 6
survival (6) 6
antineoplastic agents - pharmacology (5) 5
antineoplastic agents, immunological - adverse effects (5) 5
apoptosis - drug effects (5) 5
biochemistry & molecular biology (5) 5
carcinoma, non-small-cell lung - secondary (5) 5
diagnosis (5) 5
docetaxel (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Cancer biology & medicine, ISSN 2095-3941, 2017, Volume 14, Issue 4, pp. 341 - 347
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 04/2016, Volume 387, Issue 10027, pp. 1540 - 1550
... Castro, Marcelo Garrido, Gregory M Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled-Filhart, Edward B Garon Abstract... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Cell survival | Medical treatment | FDA approval | Health care facilities | Survival | Patients | Evidence-based medicine | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 34, pp. 4349 - 4357
Journal Article
The Lancet (British edition), ISSN 0140-6736, 08/2014, Volume 384, Issue 9944, pp. 665 - 673
Journal Article
Clinical cancer research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 1038 - 1047
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 19, pp. 1998 - 2006
Journal Article